Belantamab mafodotin
Blenrep (belantamab mafodotin) is an antibody pharmaceutical. Belantamab mafodotin was first approved as Blenrep on 2020-08-05. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
| Trade Name | Blenrep |
|---|---|
| Common Name | Belantamab mafodotin |
| Indication | multiple myeloma |
| Drug Class | Synthetic analogs of the dolastatin series; monoclonal antibodies: tumors |
